pritumumab

{
  "id": "MLC-T-ONC-016219",
  "term": "pritumumab",
  "field": "Oncology and biomedicine",
  "definition": "A naturally-produced human immunoglobulin G1 (IgG1) kappa antibody derived from a tumor-specific B-lymphocyte isolated from the regional draining lymph node of a patient with cervical carcinoma and targeted against the cell surface expressed vimentin, ecto-domain vimentin (EDV), with potential immunomodulating and antineoplastic activities. Upon administration, pritumumab targets and binds to EDV, which is expressed on a variety of tumor cell types but is not expressed by normal tissues and cells. This induces tumor cell death by antibody-dependent cell-mediated cytotoxicity (ADCC), and inhibits growth of EDV-expressing tumor cells. Pritumumab is able to penetrate the blood-brain barrier (BBB). Vimentin, an intracellular cytoskeletal protein, is overexpressed during epithelial-to-mesenchymal transition (EMT).",
  "synonyms": [
    "CLN-IgG",
    "immunoglobulin G, anti-(human vimentin) (human monoclonal CLN G11 gamma1-chain), disulfide with human monoclonal CLN G11 kappa-chain, dimer"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pritumumab/"
}